Alnemr, M., Selem, A., Elshiekh, E., Elfeky, A. (2022). Intratympanic Gentamicin Injection for Treatment of Vertigo in Intractable Meniere's Disease. The Egyptian Journal of Hospital Medicine, 89(1), 6000-6005. doi: 10.21608/ejhm.2022.266831
Mohamed Abdelmohsen Alnemr; Amira Selem Abdelazem Selem; Ezzeddin Mohamed Elshiekh; Alaa Eldin Mohamed Elfeky. "Intratympanic Gentamicin Injection for Treatment of Vertigo in Intractable Meniere's Disease". The Egyptian Journal of Hospital Medicine, 89, 1, 2022, 6000-6005. doi: 10.21608/ejhm.2022.266831
Alnemr, M., Selem, A., Elshiekh, E., Elfeky, A. (2022). 'Intratympanic Gentamicin Injection for Treatment of Vertigo in Intractable Meniere's Disease', The Egyptian Journal of Hospital Medicine, 89(1), pp. 6000-6005. doi: 10.21608/ejhm.2022.266831
Alnemr, M., Selem, A., Elshiekh, E., Elfeky, A. Intratympanic Gentamicin Injection for Treatment of Vertigo in Intractable Meniere's Disease. The Egyptian Journal of Hospital Medicine, 2022; 89(1): 6000-6005. doi: 10.21608/ejhm.2022.266831
Intratympanic Gentamicin Injection for Treatment of Vertigo in Intractable Meniere's Disease
Background: Vertigo is being treated by Intratympanic Gentamicin (ITG) among Ménière's Disease (MD) patients, but its effectiveness and safety remain controversial. Objective: To know the optimal dose and duration of intratympanic gentamicin needed to cease vertigo attacks in Ménière’s disease. Patients and Methods: At Oto-Rhino-Laryngology, and Head and Neck Surgery Departments of Zagazig University hospital,eighteen consecutive patients with disabling unilateral Ménière’s disease were included in this randomized controlled trial. The patients were divided randomly into 2 groups; Group A: 9 patients were injected with 20mg/ ml every 3 days for 6 injections, until vertigo completely controlled or presence of complications & Group B: 9 patients were injected with 40mg/ ml every 1 month for 4 injections, until vertigo completely controlled or presence of complications. Results: Twenty mg/ml ITG every 3 days in group A & 40mg/ml ITG every 1month in group B; Both doses can control vertigo, Group A: there was no significant hearing impairment but need repeated rounds of injections, Group B: there was significant hearing impairment and need less rounds of injections. Conclusion: Considering the results of using 20mg/ml ITG every 3 days in group A & 40mg/ml ITG every 1month in group B; Both doses can control vertigo. Group A: there was no significant hearing impairment but need repeated rounds of injections. Group B: there was significant hearing impairment and need less rounds of injections. Using 20mg/ml ITG every 3 days is better and safer than using 40mg/ml ITG every 1 month.